U.S. Markets closed

PowerShares Dynamic Retail ETF (PMR)


NYSEArca - Nasdaq Real Time Price. Currency in USD
Add to watchlist
35.21+0.21 (+0.60%)
At close: 4:00PM EDT
People also watch
PEJPSJPBSPICPUI
Interactive chart
Previous Close35.00
Open35.09
Bid0.00 x
Ask36.97 x 500
Day's Range35.09 - 35.21
52 Week Range33.52 - 38.86
Volume7,037
Avg. Volume3,274
Net Assets14.43M
NAV36.07
PE Ratio (TTM)N/A
Yield0.89%
YTD Return1.05%
Beta (3y)0.57
Expense Ratio (net)0.63%
Inception Date2005-10-26
Trade prices are not sourced from all markets
  • PR Newswire3 days ago

    PharmaMar Announces New Data with its Compounds Yondelis® and Lurbinectedin During ASCO 2017

    MADRID, May 19, 2017 /PRNewswire/ -- PharmaMar (MCE: PHM) will present data obtained from various clinical studies for its activated transcription inhibitors, Yondelis ® and lurbinectedin, during the 53 ...

  • Retail ETF Returns Reflect Industry Upheaval
    ETF.com10 days ago

    Retail ETF Returns Reflect Industry Upheaval

    Some 20 years ago, a low rumbling of change began to build in the retail industry. Remember when Amazon, despite losing billions of dollars a year, started to eat the market-share lunch of bookstores? There was clear disruption going on, but really in a small material way back then. However, there were those who saw the future, and extrapolated that what Amazon was doing to bookstores would happen across retail. Many scoffed.

  • PR Newswire13 days ago

    PharmaMar: Sylentis Announces New Preclinical and Clinical Data for its SYL1001 Molecule During ARVO 2017

    In the framework of the Annual Congress of the Association for Research in Vision and Ophthalmology 2017 (ARVO), being held from the 7-11 of May in Baltimore (USA), Sylentis, a pharmaceutical company from the PharmaMar Group (PHM), presents new preclinical and clinical developments with its molecule SYL1001 for the treatment of dry eye disease. This Congress will bring together more than 11,000 top eye and vision researchers and clinicians from around the world to explore cutting-edge basic and clinical science.